Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Repurposing for rare diseases
June 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

BRANFORD, Conn.—A new partnership was announced in April between BioXcel Corp. and Takeda Development Center Americas to repurpose assets across a range of orphan diseases. The partnership grants Takeda access to BioXcel’s Big Data Innovation Lab and PharmGPS Orphan Disease Suite for use in drug discovery and repurposing. The PharmGPS suite covers more than 9,000 rare and ultra-rare diseases, 4,000 to 5,000 associated genes and 1,500 disease pathways. No financial details were disclosed.
 
“We are pleased that Takeda will leverage our expertise in rare and ultra-rare diseases to support their innovation and portfolio expansion initiatives. Discovering novel applications for existing molecules is an increasingly attractive strategy to address patient needs, while capitalizing on previous investments and de-risking clinical development. Our Big Data Innovation Lab facilitates the repurposing of the most attractive candidates applicable to a given disease,” said BioXcel’s CEO and Chairman Dr. Vimal Mehta.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.